Inspection Cases: Misuse of Status Labels Leading to Serious Deviations

Lessons from Inspection Cases: Preventing Misuse of Material Status Labelling System in GMP

Effective material status labelling system in GMP environments is essential for ensuring product quality, patient safety, and regulatory compliance. Misuse, wrong status assignment, and unauthorized use of materials have been identified repeatedly during regulatory inspections as root causes of serious deviations with potential to jeopardize batch quality and market supply.

This detailed step-by-step tutorial aims to equip pharmaceutical professionals in manufacturing, quality assurance (QA), quality control (QC), supply chain, and regulatory functions with practical insights and controls learned from real-world inspection cases. These lessons apply across key regulatory jurisdictions including the US FDA, the European Medicines Agency (EMA), MHRA, and internationally recognized frameworks such as PIC/S and ICH guidelines.

1. Understanding the Fundamentals of Material Status Labelling in GMP

Before delving into specific inspection observations, it is critical to comprehend the design and function of a compliant material status labelling system in GMP. Status labelling is the frontline control in warehouses and production areas that controls the flow and use of materials. Each status label must clearly define the material’s approval stage and permitted use, for example: “Quarantine,” “Released,” “Rejected,” or “On Hold.”

According to FDA 21 CFR Parts 210 and 211, a robust material status system must prevent unauthorized use of materials by providing clear visual identifiers and supporting documentation traceability. Similarly, the EU GMP Guide, Volume 4 mandates effective segregation and labelling to prevent mix-ups and cross-contamination.

Improper labelling often originates from insufficient procedural detail, lack of training, or uncontrolled label printing and issuance. These failures quickly propagate downstream errors such as the release of out-of-specification (OOS) materials or the use of rejected components in production—a critical GMP breach.

Also Read: Status Label Design: Information, Format and Control Requirements

Key elements of a compliant status labelling system include:

Standardized label formats, colors, and wording consistent with company and regulatory requirements.
Controlled label issuance with batch- and material-specific qualifiers.
Clear linkage between status labels and electronic or paper-based batch records.
Defined responsibilities and training for all personnel handling status labels.
Procedures for immediate removal or destruction of obsolete or incorrect labels to avoid reuse.

2. Common Inspection Findings Pertaining to Misuse and Wrong Status Labels

Regulatory inspections across the US, UK, and EU frequently identify deviations caused by mismanagement of the material status labelling system in GMP. Below are recurring nonconformities documented in inspection reports and warning letters, with explanations and impact examples:

2.1 Unauthorized Use of Materials Marked “Quarantine” or “Rejected”

A significant number of inspection cases reported products manufactured using raw materials or components labeled as “quarantine” or “rejected,” indicating they were not yet approved or unsuitable for use. One notable FDA inspection cited multiple instances where quarantine status materials were released without proper quality control review or re-testing, violating PIC/S PE 009 principles on material control.

The consequences included batch stability failures and product recalls due to unidentified impurities. Root causes often were inadequate segregation and loose supervision of material movement, compounded by label reuse without authorization.

2.2 Wrong Status Labels Leading to Mix-ups in Warehouse

Misapplication of status labels—such as applying “Released” labels to non-conforming or untested batches—has caused confusion in warehouses and production lines. This misuse can cause incorrect issuance for production or packaging. Inspectors have found instances where status labels intended for validated batches were used for returned goods or materials under investigation. This error contravenes GMP requirements on documentation and traceability.

2.3 Label Damage, Obscured Information, and Lack of Removal of Old Labels

Label integrity is critical to avoid misinterpretation of material status. Inspection cases revealed damaged or illegible status labels due to poor label materials or environmental exposure such as humidity or chemical contact. Another common issue was the failure to remove old status labels when materials changed status. This situation facilitates status confusion, enabling unauthorized use or double issuance.

Also Read: Out-of-Specification (OOS) Investigations in QC: A GMP Playbook

3. Step-by-Step Corrective Actions to Prevent Misuse and Wrong Status Labels

To address risks related to misuse, wrong status, and unauthorized use of materials, pharmaceutical establishments should institute a structured and detailed action plan. Below is a stepwise tutorial to help organizations enhance control and compliance in their material status labelling systems.

Step 1: Conduct a Comprehensive Risk Assessment of the Current Labelling System

Begin by mapping all points where material status labels are generated, issued, applied, changed, removed, and archived. Include the warehouse, production, QC, and QA release areas. Identify potential failure mode effects, such as unauthorized label printing or missing label updates after test results. Utilize principles from ICH Q9 Quality Risk Management to categorize risks by severity, occurrence, and detection.

Step 2: Revise and Standardize Material Status Label Formats and Procedures

Design labels with clear, unambiguous text and use color-coding consistent with industry best practices and internal standards. For example, red for “Rejected,” yellow for “Quarantine,” green for “Released,” and blue for “Hold.” Develop or update SOPs to include:

Detailed steps for label ordering, printing, and issuance control.
Instructions for application and removal of status labels on containers.
Procedures for label verification and reconciliation during warehouse movements.
Requirements for immediate notification to QA upon any label anomaly.

Step 3: Implement Electronic Barcode Systems to Complement Physical Labels

Many pharmaceutical companies integrate barcode or RFID technology to reduce human errors associated with manual label reading and application. These technologies help in:

Real-time status verification during picking and issuing.
Automatic updates to inventory management software reflecting material disposition.
Audit trails documenting which personnel performed status changes.

Step 4: Train and Qualify Personnel on Correct Labelling Practices

Provide thorough, role-specific training targeted at warehouse staff, production operators, QA, and QC analysts. Training must cover:

The criticality of adhering to the material status labelling system in GMP.
How to identify misuse, wrong status, and unauthorized use scenarios.
Actions to take when discrepant labels are found.
Procedures for reporting and correcting labelling deviations.

Also Read: Case Studies: Packaging Errors That Led to Recalls

Regular competency assessments and refresher training are essential to maintain awareness.

Step 5: Strengthen Oversight Through Periodic Audits and Trend Analysis

Establish audit programs focusing on label controls within warehouses and production lines. Review batch records, labels applied, and label issuance logs to verify compliance. Employ trend analysis on audit results and deviation reports to identify systemic issues related to misuse or incorrect labelling. Implement continuous improvement initiatives based on data-driven findings.

Step 6: Enforce Immediate Corrective and Preventive Actions (CAPA) for Any Labeling Deviations

In case of observed misuse, wrong status, or unauthorized use, initiate CAPA procedures swiftly. This includes investigating root causes, quarantining impacted materials or batches, and performing risk assessments for product quality and patient safety. Regulatory authorities expect thorough documentation and evidence that CAPAs effectively prevent recurrence, as per EMA GMP Compliance Guidance.

4. Summary of Best Practices to Sustain a Robust Material Status Labelling System

Proper management of material status labels is a foundational component of pharmaceutical GMP systems that directly impacts product quality and compliance. As demonstrated through inspection case reviews, even small oversights in labelling can escalate to major GMP deviations, inspection citations, and market risks.

To summarize a strong approach:

Design and implement standardized, unambiguous status label formats respected throughout the supply chain.
Control physical and electronic label issuance with strict access and authorization protocols.
Train personnel frequently and rigorously on label-related procedures.
Integrate technology to reduce manual errors and enable traceability.
Regularly audit label application and management activities and take prompt CAPA actions.

Adoption of these controls will minimize the risk of misuse, wrong status, and unauthorized use of materials, thereby enhancing compliance with GMP standards and inspection readiness across the US, UK, and EU regulatory landscapes.